- Design
- Single-centre prospective paired diagnostic study
- Population
- 66 biopsy-eligible men with PI-RADS 3 lesions and at least one high-risk feature
- Primary outcome
- Detection of clinically significant prostate cancer
- Effect
- PSMA-targeted 15% vs MRI-targeted 6%; difference 9% (95% CI 2% to 18%)
This single-centre prospective paired study enrolled biopsy-eligible men with an equivocal PI-RADS 3 lesion and at least one high-risk feature. All had PSMA PET/MRI before transperineal biopsy, which included MRI-targeted cores, PSMA-targeted cores where the scan was positive, and systematic cores. Sixty-six of 83 men completed the pathway.
PSMA PET was positive in 21 men (32%). PSMA-targeted biopsy found clinically significant cancer in 10 men (15%) against 4 (6%) with MRI-targeted biopsy, a difference of 9 percentage points (95% CI 2 to 18). Sensitivity and negative predictive value of PSMA PET were both 100%, and specificity 82%. None of the 45 men with a negative scan had significant cancer.
PI-RADS 3 lesions are a frequent source of uncertainty and unnecessary biopsies. These results are promising, but 66 men from one centre using one tracer are not enough to justify skipping biopsy on a negative scan, as the authors themselves say. PSMA PET access and cost also limit its use in India.
- Consider PSMA PET in men with PI-RADS 3 lesions and high-risk features where available, as a research-stage triage tool.
- Continue to biopsy PI-RADS 3 lesions with high-risk features under current practice; this study does not justify omitting biopsy.
- Use PSA density and other risk factors to decide which PI-RADS 3 lesions need biopsy.
- Watch for larger multicentre studies before changing pathways.
Why it matters
Equivocal MRI lesions generate many negative biopsies; a reliable rule-out test would spare men that procedure.
Don't overread it
With 66 men and few cancers, a 100% negative predictive value is fragile; one missed cancer would change it.
The statistics, in plain English
A negative predictive value of 100% came from 45 men with no significant cancer. With so few cancers overall (10), the true value in a larger group could be meaningfully lower.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for urology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free